Fortrea signed a collaboration with Prague‑based SCTbio to offer combined clinical study and cell‑and‑gene therapy (CGT) manufacturing services, targeting developers that need integrated trial supply and production capacity. Separately, Pillar Biosciences and AstraZeneca expanded their liquid biopsy partnership into China, partnering with Shanghai Zhengu Biological Technology to validate Pillar's plasma‑based tumor profiling panels for local laboratories. Both moves highlight industry focus on scaling specialized manufacturing and diagnostic capabilities to support global trials and localized regulatory and clinical needs.